- Home
- UMC vs UTHR Comparison
UMC vs UTHR Comparison
Compare UMC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMC
- UTHR
- Stock Information
- Founded
- UMC 1980
- UTHR 1996
- Country
- UMC Taiwan
- UTHR United States
- Employees
- UMC N/A
- UTHR N/A
- Industry
- UMC Semiconductors
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- UMC Technology
- UTHR Health Care
- Exchange
- UMC Nasdaq
- UTHR Nasdaq
- Market Cap
- UMC 16.9B
- UTHR 16.1B
- IPO Year
- UMC 2000
- UTHR 1999
- Fundamental
- Price
- UMC $6.06
- UTHR $367.97
- Analyst Decision
- UMC Sell
- UTHR Buy
- Analyst Count
- UMC 4
- UTHR 14
- Target Price
- UMC $7.40
- UTHR $378.36
- AVG Volume (30 Days)
- UMC 10.6M
- UTHR 280.3K
- Earning Date
- UMC 01-21-2025
- UTHR 02-19-2025
- Dividend Yield
- UMC 7.63%
- UTHR N/A
- EPS Growth
- UMC N/A
- UTHR 25.10
- EPS
- UMC 0.13
- UTHR 22.72
- Revenue
- UMC $7,143,186,732.00
- UTHR $2,756,200,000.00
- Revenue This Year
- UMC $6.20
- UTHR $26.19
- Revenue Next Year
- UMC $8.02
- UTHR $10.79
- P/E Ratio
- UMC $10.36
- UTHR $16.19
- Revenue Growth
- UMC N/A
- UTHR 25.04
- 52 Week Low
- UMC $5.88
- UTHR $208.62
- 52 Week High
- UMC $9.00
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- UMC 34.57
- UTHR 53.51
- Support Level
- UMC $6.09
- UTHR $357.25
- Resistance Level
- UMC $6.42
- UTHR $372.34
- Average True Range (ATR)
- UMC 0.15
- UTHR 8.70
- MACD
- UMC -0.02
- UTHR 0.91
- Stochastic Oscillator
- UMC 19.89
- UTHR 79.59
About UMC United Microelectronics Corporation (NEW)
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2023 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the us, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.